Cargando…

Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two interrelated inflammatory diseases affecting patients above 50 years of age. Patients with GCA suffer from granulomatous inflammation of medium- to large-sized arteries. This inflammation can lead to severe ischemic complications (e...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Geest, Kornelis S. M., Sandovici, Maria, Nienhuis, Pieter H., Slart, Riemer H. J. A., Heeringa, Peter, Brouwer, Elisabeth, Jiemy, William F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207253/ https://www.ncbi.nlm.nih.gov/pubmed/35733858 http://dx.doi.org/10.3389/fmed.2022.902155

Ejemplares similares

Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica
por: van der Geest, Kornelis S M, et al.
Publicado: (2021)

Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica
por: Reitsema, Rosanne D., et al.
Publicado: (2023)

Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica
por: van Sleen, Yannick, et al.
Publicado: (2019)

A Case of Clinical Uncertainty Solved: Giant Cell Arteritis with Polymyalgia Rheumatica Swiftly Diagnosed with Long Axial Field of View PET
por: Nienhuis, Pieter H., et al.
Publicado: (2022)

Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica
por: van der Geest, Kornelis S M, et al.
Publicado: (2022)

Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica
por: van Sleen, Yannick, et al.
Publicado: (2022)

Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica
por: van Sleen, Yannick, et al.
Publicado: (2022)

Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica
por: Reitsema, Rosanne D., et al.
Publicado: (2022)

Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022)

Giant cell arteritis with polymyalgia rheumatica on FDG‐PET/CT
por: Baba, Akira, et al.
Publicado: (2017)

Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment
por: Esen, Idil, et al.
Publicado: (2021)

Optimal management of giant cell arteritis and polymyalgia rheumatica
por: Charlton, Rodger
Publicado: (2012)

Genetic epidemiology: Giant cell arteritis and polymyalgia rheumatica
por: Gonzalez-Gay, Miguel A
Publicado: (2001)

Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update
por: Nesher, Gideon, et al.
Publicado: (2016)

Liver involvement in polymyalgia rheumatica and giant cell arteritis
por: Hysa, Elvis, et al.
Publicado: (2020)

Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis
por: Esen, Idil, et al.
Publicado: (2021)

Phenotypic, transcriptomic and functional profiling reveal reduced activation thresholds of CD8(+) T cells in giant cell arteritis
por: Reitsema, Rosanne D, et al.
Publicado: (2022)

Familial aggregation of longevity in giant cell arteritis and polymyalgia rheumatica
por: Milchert, Marcin, et al.
Publicado: (2020)

Predictive Factors of Giant Cell Arteritis in Polymyalgia Rheumatica Patients
por: Ramon, André, et al.
Publicado: (2022)

Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort
por: Esen, Idil, et al.
Publicado: (2023)

Comment on: Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis: reply
por: Esen, Idil, et al.
Publicado: (2022)

A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL‐40/Interleukin‐13 Receptor α2 Axis
por: van Sleen, Yannick, et al.
Publicado: (2021)

Need and value of targeted immunosuppressive therapy in giant cell arteritis
por: Sandovici, Maria, et al.
Publicado: (2022)

Giant Cell Arteritis Mimicking Polymyalgia Rheumatica: A Challenging Diagnosis
por: Ohta, Ryuichi, et al.
Publicado: (2022)

Metabolic bone health considerations in giant cell arteritis and polymyalgia rheumatica
por: Low, Candice, et al.
Publicado: (2023)

Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases
por: Pujades-Rodriguez, Mar, et al.
Publicado: (2016)

Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis
por: Emamifar, Amir, et al.
Publicado: (2021)

Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis: Need for Standardization
por: Stellingwerff, Menno D., et al.
Publicado: (2015)

Distinct macrophage phenotypes skewed by local granulocyte macrophage colony‐stimulating factor (GM‐CSF) and macrophage colony‐stimulating factor (M‐CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis
por: Jiemy, William F, et al.
Publicado: (2020)

Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?
por: Toussirot, Éric, et al.
Publicado: (2016)

Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis
por: Smutny, Tomas, et al.
Publicado: (2019)

The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population
por: Yates, Max, et al.
Publicado: (2016)

Antimitochondrial Antibodies and Primary Biliary Cholangitis in Patients with Polymyalgia Rheumatica/Giant Cell Arteritis
por: Manzo, Ciro, et al.
Publicado: (2021)

Polymyalgia rheumatica and giant cell arteritis with intracranial involvement postvaccination anti-COVID-19
por: Arias, Manuel, et al.
Publicado: (2022)

Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis: A Systematic Review and Meta-analysis
por: van der Geest, Kornelis S. M., et al.
Publicado: (2020)

Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis
por: van Sleen, Yannick, et al.
Publicado: (2017)

Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis
por: van Sleen, Yannick, et al.
Publicado: (2019)

Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis
por: van der Geest, K. S. M., et al.
Publicado: (2020)

Widespread headache as the first clinical manifestation of giant cell arteritis in patients affected by polymyalgia rheumatica
por: Manzo, Ciro
Publicado: (2016)

Can active sun exposure decrease the risk of giant cell arteritis and polymyalgia rheumatica in women?
por: Gisslander, Karl, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uavaqcdn12e2bip48ddcmum5io